





OPERATION WARP SPEED VACCINE DELIVERY MILESTONES

AUTHORIZATION - APPROVAL



Phase 3 Trials

Randomized, double-blind, placebo-controlled studies with more than 30k participants each, including diverse populations, providing rapid data collection



Data Safety Monitoring Board

Independent board evaluates data from ongoing Phase 3 trial, advises manufacturer whether pre-specified success criteria is met

Emergency Use Authorization (EUA)

Granted by the FDA following a recommendation by the Vaccines and Related **Biological Products Advisory Committee and** an independent analysis of drug manufacturing facilities, processes and drug product data





National Academies of Science, Engineering and Medicine

Informs the CDC Advisory Committee on Immunization Practices (ACIP) on which populations receive priority for vaccines



Vaccine Priority

ACIP recommends vaccine priority to the CDC director. who reviews and recommends to the HHS Secretary

PRIORITIZATION - ALLOCATION



HHS Secretary

Endorses recommendation and staffs policy for approval to National Security Council



Allocation

Administration sites

Public health clinic

Long term care facility

Pharmacy

Hospital

Distribution based on census data for prioritized groups; drives the delivery of available doses to states. tribes, territories, localities and federal agencies



Jurisdictions/Federal Agencies

Execute federal priority guidance to identify points for vaccine delivery and administration

DISTRIBUTION - ADMINISTRATION

Initial dose administered at various locations:





Needles, syringes, alcohol swabs, etc.

Jurisdictions provide dosing information to CDC data clearing

house through immunization information systems and partner

systems; patient data is de-identified with no personal



packages in ready-to-ship kits



Delivers vaccine and supplies to administration sites

Second Dose Tracking

As most vaccines require two doses – 21 to 28 days apart from the same manufacturer, second dose reminders will be generated through existing IT systems

- Federally qualified health center
- Healthcare provider (doctors' office)
- Mass vaccination site
- Indian Health Service



Pharmacovigilance

Post-vaccination monitoring continues for 24 months to detect, assess, understand, and prevent adverse effects; coordinated with vaccine companies, the CDC and FDA through multiple vaccine safety systems and V-SAFE



Data IT/Systems

identifying or health information



Biologics Licensure Application (BLA)

Includes safety and efficacy data along with product, manufacturing and clinical studies information to consider full approval, potentially following six months of additional monitoring





OPERATION WARP SPEED VACCINE DISTRIBUTION PROCESS

IN SUPPORTING THE DISTRIBUTION & ADMINISTRATION OF COVID-19 VACCINES, OWS HAS FOUR KEY GOALS, TENETS, AND ARCHITECTURE



Ensure safety and effectiveness of COVID-19 vaccines



Reduce morbidity and mortality of COVID-19 disease through effective and efficient distribution of COVID-19 vaccines



Support rapid vaccine distribution based on CDC guidance for states immunizations services



Assist with the return to pre-pandemic quality of life

DISTRIBUTION AND ADMINISTRATION OF A COVID-19 VACCINE FOUR KEY TENETS

times in the process o	TY econdary item kits are at all if distribution and ensuring the zed groups as determined by		COVERAGE Deliver vaccines beyond the normal brick and mortar facilities, including potential mobile or on-site delivery of vaccine to long-term healthcare facilities and other hard to reach populations
UPTAKE How many vaccines w per day to match supp	vere administered per location ply with demand		TRACEABILITY Confirm which of the approved vaccines were administered: • Regardless of location (private/public) • Reminder to return for second dose • Administer the correct second dose
TRIALS	<section-header> FDA Based on data from clinical trials, vaccine candidate is submitted for mergency Use Authorization (EUA) or Biologics License Application (BLA) • Reviews EUA/BLA application (BLA) • Reviews EUA/BLA application • Approves EUA/BLA application • Approves EUA/BLA application • Pharmacovigilance</section-header>	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	<image/> <section-header><section-header><section-header><section-header><section-header><text></text></section-header></section-header></section-header></section-header></section-header>
	\bigcirc		



ADMINISTRATION SITES

Vaccines, upon EUA/BLA, are ready to ship to:

- Pharmacies
- Nursing homes
- Public Clinics
- Hospitals
- Doctor's offices and Mobile Clinics
- Military Treatment Facilities

DISTRIBUTION FACILITIES

Vaccines & associated ancillary kits (syringes, needles, and alcohol swabs) will be shipped concurrently to distribution depots and facilities


DISTRIBUTOR

- Maximize use of existing pharmaceutical distribution infrastructure
- Central Distributor established for kitting & distribution operations
- IT infrastructure supports ordering, distribution, administration, and tracking end-to-end

PHARMACOVIGILANCE (FDA & CDC)

24 month post trial monitoring for adverse effects/additional safety feature






Phase III Clinical Trials


Distribution

R&D + Preclinical Trials Vaccine Candidate/s Identified Phase I Clinical Trials

COVID-19 Vaccination Record Card

Please keep this record card, which includes medical information about the vaccines you have received.





Reminder! Return for a second dose! ¡Recordatorio! ¡Regrese para la segunda dosis!

Vaccine	Date / Fecha		
COVID-19 vaccine	//		
Vacuna contra el COVID-19	mmddyy		
Other	//		
Otra			

Bring this vaccination record to every vaccination or medical visit. Check with your health care provider to make sure you are not missing any doses of routinely recommended vaccines.

For more information about COVID-19 and COVID-19 vaccine, visit **cdc.gov**/ **coronavirus/2019-ncov/index.html**.

You can report possible adverse reactions following COVID-19 vaccination to the Vaccine Adverse Event Reporting System (VAERS) at vaers.hhs.gov. Lleve este registro de vacunación a cada cita médica o de vacunación. Consulte con su proveedor de atención médica para asegurarse de que no le falte ninguna dosis de las vacunas recomendadas.

Para obtener más información sobre el COVID-19 y la vacuna contra el COVID-19, visite espanol.cdc.gov/coronavirus/2019-ncov/ index.html.

Puede notificar las posibles reacciones adversas después de la vacunación contra el COVID-19 al Sistema de Notificación de Reacciones Adversas a las Vacunas (VAERS) en **vaers.hhs.gov**.

YOU CALL_THE Vaccine Administration: SHOES Needle Gauge and Length

Vaccines must reach the desired tissue to provide an optimal immune response and reduce the likelihood of injection-site reactions. Needle selection should be based on the:

Route

- Age
- Gender and weight for adults (19 years and older)
 Injection site
- The following table outlines recommended needle gauges and lengths. In addition, clinical judgment should be used when selecting needles to administer injectable vaccines.

Route	Age	Needle gauge and length	Injection site
Subcutaneous injection	All ages	23–25-gauge 5/8 inch (16 mm)	Thigh for infants younger than 12 months of age ¹ ; upper outer triceps area for persons 12 months of age and older
Intramuscular injection	Neonate, 28 days and younger	22–25-gauge 5/8 inch (16 mm ²)	Vastus lateralis muscle of anterolateral thigh
	Infants, 1–12 months	22–25-gauge 1 inch (25 mm)	Vastus lateralis muscle of anterolateral thigh
	Toddlers, 1–2 years	22–25-gauge 1–1.25 inches (25–32 mm)	Vastus lateralis muscle of anterolateral thigh ³
		22–25-gauge 5/8 ² –1 inch (16–25 mm)	Deltoid muscle of arm
	Children, 3–10 years	22–25-gauge 5/8 ² –1 inch (16–25 mm)	Deltoid muscle of arm ³
		22–25-gauge 1–1.25 inches (25–32 mm)	Vastus lateralis muscle of anterolateral thigh
	Children, 11–18 years	22–25-gauge 5/8 ² –1 inch (16–25 mm)	Deltoid muscle of arm ^{3,5}
	Adults, 19 years and older 130 lbs (60 kg) or less 130–152 lbs (60–70 kg) Men, 152–260 lbs (70–118 kg) Women, 152–200 lbs (70–90 kg) Men, 260 lbs (118 kg) or more Women, 200 lbs (90 kg) or more	22–25-gauge 1 inch (25 mm ⁴) 1 inch (25 mm) 1–1.5 inches (25–38 mm) 1–1.5 inches (25–38 mm) 1.5 inches (38 mm) 1.5 inches (38 mm)	Deltoid muscle of arm ^{3,5}

¹ May be administered into the upper outer triceps area if necessary

² If the skin is stretched tightly and subcutaneous tissues are not bunched

⁴ Some experts recommend a 5/8-inch needle for men and women weighing less than 60 kg, if used, skin must be stretched tightly and subcutaneous tissues must not be bunched. ⁵ The vastus lateralis muscle in the anterolateral thigh can also be used. Most adolescents and adults will require a 1- to 1.5-inch (25–38 mm) needle to ensure intramuscular administration.



Reference: Advisory Committee on Immunization Practices General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html

³ Preferred site